A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested.
Video content above is prompted by the following question:
a. BTK inhibitors are currently utilized in other disease states. What are the important clinical considerations with BTK inhibitors that clinicians should know?
b. How would the introduction of an oral therapy for CSU influence your treatment decisions?
Earlier Food Introduction Dramatically Reduces Peanut, Egg, Milk Allergy Rates in Infants
July 30th 2025When updated food allergy prevention guidelines were directly provided to families, they led to earlier allergen introduction in infants and significantly reduced the prevalence of IgE-mediated peanut, egg, and cow's milk allergies.
Read More
Patients With Chronic Spontaneous Urticaria Seek Better Treatment Beyond Current Options
July 28th 2025Patients with chronic spontaneous urticaria experience inadequate symptom control and significant emotional burdens despite various treatment approaches, highlighting an urgent need for more effective and sustained therapies to improve their quality of life.
Read More
AllergyAware E-Learning Training Program Boosts Anaphylaxis Preparedness in School Staff
July 25th 2025The AllergyAware e-learning course effectively trained school personnel on anaphylaxis management, significantly improving their knowledge and confidence in using epinephrine auto-injectors, despite some technical and pacing issues reported by users.
Read More
Specialty Drug Costs Drive Medicare Part D Dermatology Expenditures
July 22nd 2025The rapidly increasing prescriptions for expensive specialty medications, rather than their price growth, are the primary driver of escalating dermatology Medicare Part D expenditures, necessitating policies that balance innovation, access, and affordability.
Read More